Iron supplementation in a large Swiss Cohort of Inflammatory Bowel Disease patients demonstrates a shift form oral to intravenous therapy over time

Background and Aims: The 2007 European Crohn's and Colitis Organization guidelines on anemia in inflammatory bowel disease (IBD) favour intravenous (iv) over oral (po) iron supplementation due to better effectiveness and tolerance. We aimed to determine the percentage of IBD patients under iron supplementation therapy and the dynamics of prescription habits (iv versus po) over time. Methods: Helsana, a leading Swiss health insurance company provides coverage for approximately 18% of the Swiss population, corresponding to about 1.2 million enrollees. Patients with Crohn's disease (CD) and ulcerative colitis (UC) were analyzed from the anonymised Helsana database. Results: In total, 629 CD (61% female) and 398 UC (57% female) patients were identified, mean observation time was 31.8 months for CD and 31.0 months for UC patients. Of the entire study population, 27.1% were prescribed iron (21.1% in males and 31.1% in females). Patients treated with IBD-specific drugs (steroids, immunomodulators, anti-TNF agents) were more frequently treated with iron compared to patients without any medication (35.0% vs. 20.9%, OR 1.91, 95%-CI 1.41-2.61). The prescription of iv iron increased from 2006/2007 (48.8% of all patients receiving any iron priscription) to 65.2% in 2008/2009 by a factor of 1.89. Conclusions: One third of the IBD population was treated with iron supplementation. A gradual shift from oral to iv iron was observed over time. This switch in prescription habits goes along with the implementation of the ECCO consensus guidelines on anemia in IBD.

Integrative taxonomy of the Formica rufa group (Hymenoptera: Formicidae)

RESUME :Les fourmis du groupe Formica rufa, ou fourmis des bois, ainsi appelées en raison de leur préférence pour les écosystèmes forestiers, sont parmi les fourmis les plus fascinantes et les plus étudiées d'Europe. Ces fourmis jouent un rôle clé dans la plupart des forêts dans lesquelles elles vivent et sont considérées comme étant les meilleurs bioindicateurs de ces milieux. Pour ces raisons, les fourmis des bois sont protégées par la loi dans de nombreux pays européens, y compris en Suisse. Cependant, malgré leur protection, ces fourmis sont inscrites sur la liste rouge des espèces menacées dans plusieurs pays d'Europe et il est donc indispensable de bien les connaître afin de mieux les protéger.À l'heure actuelle, on considère que le groupe Formica rufa est composé de six espèces distinctes : F. rufa, F. polyctena, F. lugubris, F. paralugubris, F. aquilonia et F. pratensis. Toutefois, malgré la grande quantité d'études effectuées sur ces espèces, la systématique et l'identification des fourmis des bois sont toujours sujettes à discussion. Ceci est essentiellement dû au fait que ces espèces sont morphologiquement similaires et qu'elles sont parfois capables de s'hybrider ou de former des colonies mixtes.Une des conditions fondamentales pour toute étude en biologie de la conservation est l'identification correcte des espèces à protéger. Avec cette étude, nous désirons donc dénouer les problèmes liés à la systématique des fourmis des bois et analyser la diversité de ces espèces en adoptant une approche multidisciplinaire.Nous avons d'abord étudié la distribution des espèces jumelles F. lugubris et F. paralugubris dans les Álpes italiennes en re-analysant l'une des plus grandes collections de références sur ces espèces, déposée à l'Université de Pavie, Italie, et en récoltant de nouveaux échantillons sur le terrain. Nos analyses ont montré que F, paralugubris, décrite récemment et souvent «oubliée »par les chercheurs, est bien présente dans les Alpes et vit souvent en sympathie avec F. lugubris. Ensuite nous avons développé un outil moléculaire basé sur l'ADN mitochondrial pour une identification rapide et efficace de ces deux espèces. Au vu des bons résultats, nous avons étendu nos analyses génétiques (microsatellites) à toutes les espèces du groupe F. rufa, ce qui nous a permis de montrer que les outils moléculaires sont très efficaces pour identifier ces fourmis. En outre, nos analyses ont mis en évidence la présence d'une nouvelle espèce cryptique (appelée F. lugubris-X) au sein du Parc National Suisse. L'existence d'une nouvelle espèce peut avoir une grande influence sur les projets de conservation en faveur de ces espèces. Nous avons donc décidé de confirmer ce résultat avec des analyses comportementales et des analyses chimiques basées sur les phéromones sexuelles des différentes espèces, y compris F. lugubris-X. Les deux approches confirment nos données génétiques et indiquent que F. lugubris-X représente bel et bien une nouvelle espèce de fourmis des bois dans les Alpes Suisses.Les résultats de cette étude ont une grande importance du point de vue de la biodiversité. En plus, ils livrent aux futurs chercheurs des outils fiables pour l'identification des fourmis des bois et ouvrent de captivantes perspectives pour une meilleure protection de ces insectes et, par conséquent, de nos écosystèmes forestiers. .Abstract :Mound building red wood ants (species of the Formica rufa group) belong to one of the most studied groups of ants in Europe and have fundamental roles and positive effects in forested habitats of the northern hemisphere. In addition, they are considered among the most promising bioindicators of forest ecosystems. Because of their importance, these ants are protected by law in many European countries, including Switzerland. However, despite this protection, they are included on the red list of threatened species edited by the International Union for Conservation of Nature (IUCN) and on the red list of some particular countries like Switzerland. Because of their similar morphology and a high intraspecific variability, the morphological identification of these species can be quite complicated. In addition, they are sometimes able to hybridize or to form mixed colonies. Consequently, the taxonomy of this group of ants has been much debated during the past decades. Based on a phylogenetic study, today the group is considered to count six species in Europe: F. rufa, F. po/yctena, F. lugubris, F. paralugubris, F. aquilonia and F. pratensis. Nevertheless, the taxonomy of the group is often neglected mainly due to the lack of reliable and easy to use identification methods.Considering the importance of correct species assessment in conservation biology, in this study we want to disentangle the taxonomical difficulties within the Formica rufa group and to clarify the diversity of these protected ants, by using an integrative approach.We first analyzed the distribution of .the sibling species F. lugubris and F. paralugubris in the Italian Alps by collecting new samples on the field and by examining one of the major red wood ant collections, which is deposited at the University of Pavia, Italy. After that, we developed a molecular tool based on mitochondria) DNA, which provides a reliable and easy-to-use technique for the identification of F. lugubris and F. paralugubris. Afterwards, we extended the use of molecular markers for species identification to the whole F. rufa group and made a microsatellite analysis. Results confirm that molecular markers are consistent tools for species identification and that the six known species represent six different genetic pools. In addition, genetic data highlighted the existence of a new cryptic species in the Swiss Alps, called Formica lugubris-X.The presence of a new species can have a great influence on future conservation plans in favour of these protected ants and consequently for forested habitats. We therefore completed molecular data by behavioural (pupae recognition) and chemical analyses based on six pheromones of the entire F. rufa group. Both approaches are in accordance to genetic results and confirm that F. lugubris-X really represents a new cryptic species of red wood ant within the Swiss National Park (Eastern Swiss Alps).Results obtained in this study have a great importance in terms of biodiversity. Moreover, they provide important taxonomical information, reliable tools for species identifications and future perspectives for a consequent conservation of red wood ant species.

La normalisation des services aux Etats-Unis et en Europe : une analyse institutionnelle des formes d'autorité privée

This chapter explores the institutional environments in which standards for the service sector are expected to support the rise of a global knowledgebased economy. The analysis relies on global political economy approaches to extend to the area of services standards the assumption that the process of globalisation is not opposing states and markets, but a joint expression of both of them including new patterns and agents of structural change through formal and informal power and regulatory practices. It analyses how services standards gain authority in the institutional environment in Europe and in the United States and the extent to which this authority is recognised at the transnational level. In contrast to conventional views opposing the European and American standardisation systems, the chapter shows that institutional developments of services standards are likely to face trade-offs and compromises across those systems.

6

L'étude sociologique des émotions Le zap d'Élizabeth Hubert La fabrique de la colère Contextes d'action et perceptions sociales de la colère

Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression.

Wound healing proceeds by the concerted action of a variety of signals that have been well identified. However, the mechanisms integrating them and coordinating their effects are poorly known. Herein, we reveal how PPARbeta/delta (PPAR: peroxisome proliferator-activated receptor) follows a balanced pattern of expression controlled by a crosstalk between inflammatory cytokines and TGF-beta1. Whereas conditions that mimic the initial inflammatory events stimulate PPARbeta/delta expression, TGF-beta1/Smad3 suppresses this inflammation-induced PPARbeta/delta transcription, as seen in the late re-epithelialization/remodeling events. This TGF-beta1/Smad3 action involves an inhibitory effect on AP-1 activity and DNA binding that results in an inhibition of the AP-1-driven induction of the PPARbeta/delta promoter. As expected from these observations, wound biopsies from Smad3-null mice showed sustained PPARbeta expression as compared to those of their wild-type littermates. Together, these findings suggest a mechanism for setting the necessary balance between inflammatory signals, which trigger PPARbeta/delta expression, and TGF-beta1/Smad3 that governs the timely decrease of this expression as wound healing proceeds to completion.

Effect of a small dose of alcohol on the endurance performance of trained cyclists.

AIM: The aim of this study was to investigate the effect of an acute small ethanol (EtOH) dose (0.5 ml EtOH/kg fat-free mass, combined with carbohydrate) in a drink on endurance performance of trained cyclists. METHODS: Thirteen well-trained male cyclists took part in this study. A 60-min cycling endurance performance test (time trial) was performed in a calorimetric chamber after drinking an EtOH (30 +/- 1.8 ml) or a non-EtOH control (C) drink. RESULTS: Overall, EtOH induced a significant decrease in the average cycling power output (PO) (EtOH: 233 +/- 23 W versus C: 243 +/- 24 W, P < 0.01). The time course of mechanical PO showed an early decrease during the EtOH trial as compared to C (P < 0.01). Due to the lower PO, oxygen consumption, carbon dioxide production and glucose oxidation were significantly lower (P < 0.05) as compared to C. Relative to PO, heart rate response and ratings of perceived exertion (RPE) were increased by EtOH as compared to C (P < 0.05). In contrast, EtOH did not influence gross work efficiency, glycaemia and blood lactate concentration. CONCLUSIONS: These results show that the acute low dose of EtOH decreased endurance performance. An increase of cardio-vascular strain and psychobiological mechanisms may explain this decrease of endurance performance.

Transcriptional repression of peroxisome proliferator-activated receptor beta/delta in murine keratinocytes by CCAAT/enhancer-binding proteins.

The roles of peroxisome proliferator-activated receptors (PPARs) and CCAAT/enhancer-binding proteins (C/EBPs) in keratinocyte and sebocyte differentiation suggest that both families of transcription factors closely interact in the skin. Initial characterization of the mouse PPARbeta promoter revealed an AP-1 site that is crucial for the regulation of PPARbeta expression in response to inflammatory cytokines in the skin. We now present evidence for a novel regulatory mechanism of the expression of the PPARbeta gene by which two members of the C/EBP family of transcription factors inhibit its basal promoter activity in mouse keratinocytes. We first demonstrate that C/EBPalpha and C/EBPbeta, but not C/EBPdelta, inhibit the expression of PPARbeta through the recruitment of a transcriptional repressor complex containing HDAC-1 to a specific C/EBP binding site on the PPARbeta promoter. Consistent with this repression, the expression patterns of PPARbeta and C/EBPs are mutually exclusive in keratinocytes of the interfollicular epidermis and hair follicles in mouse developing skin. This work reveals the importance of the regulatory interplay between PPARbeta and C/EBP transcription factors in the control of proliferation and differentiation in this organ. Such insights are crucial for the understanding of the molecular control regulating the balance between proliferation and differentiation in many cell types including keratinocytes.

Epithelium-mesenchyme interactions control the activity of peroxisome proliferator-activated receptor beta/delta during hair follicle development.

Hair follicle morphogenesis depends on a delicate balance between cell proliferation and apoptosis, which involves epithelium-mesenchyme interactions. We show that peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) and Akt1 are highly expressed in follicular keratinocytes throughout hair follicle development. Interestingly, PPARbeta/delta- and Akt1-deficient mice exhibit similar retardation of postnatal hair follicle morphogenesis, particularly at the hair peg stage, revealing a new important function for both factors in the growth of early hair follicles. We demonstrate that a time-regulated activation of the PPARbeta/delta protein in follicular keratinocytes involves the up-regulation of the cyclooxygenase 2 enzyme by a mesenchymal paracrine factor, the hepatocyte growth factor. Subsequent PPARbeta/delta-mediated temporal activation of the antiapoptotic Akt1 pathway in vivo protects keratinocytes from hair pegs against apoptosis, which is required for normal hair follicle development. Together, these results demonstrate that epithelium-mesenchyme interactions in the skin regulate the activity of PPARbeta/delta during hair follicle development via the control of ligand production and provide important new insights into the molecular biology of hair growth.

Défi pour la démocratie et changements environnementaux globaux

Les difficultés que connaissent les démocraties représentatives occidentales sont tout aussi sévères que multiples. Le mouvement de néolibéralisation du monde qui a consisté à concevoir les Etats comme de simples agents économiques a puissamment contribué à éroder la confiance des citoyens en leurs institutions nationales et territoriales. Et pourtant cet amoncellement de difficultés et de crises n'a pas affaibli l'idéal démocratique...

Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07)

Background: Single agent DTIC is the standard therapy for metastatic melanoma (MM) with response rates of 5−20%. Temozolomide (Tem) as an oral drug has shown equal efficacy in phase III trials. Preclinical models have shown an inhibitory effect for bevacizumab (Bev) on the proliferation of melanoma cells as well as on sprouting endothelial cells. Therefore, a therapeutic approach that combines angiogenesis inhibitors with cytotoxic agents may provide clinical benefit in MM. Methods: Design: Multicenter phase II trial. Primary endpoint: Clinical benefit (CR, PR and SD) at 12 weeks; secondary endpoints: best overall response by RECIST, response duration, progression free survival, adverse events, survival after 6 months and overall survival. Sample size was calculated according to Simon's two stage optimal design (5% significance level and 80% power) with an overall sample size of 62 patients (pts) to test H0: 20% versus H1: 35% rate of clinical benefit. Response assessment was done every 6 weeks (3 cycles). Eligibility: Stage IV MM, ECOG PS 0−2, no prior treatment for metastatic disease. Treatment regimen: One cycle consisted of Tem at 150 mg/m2 days 1−7 po and Bev at 10 mg/kg day 1 over 30 min iv and was repeated every 2 weeks until progression or unacceptable toxicity. Results: Between January 2008 and April 2009, 62 pts (40 male/22 female) at a median age of 61 years (range 30−86) with stage IV (M1a:4, M1b:12, M1c:46) melanoma were enrolled in 9 centers. The first 50 pts, who received 415 cycles are included in this interim report. The overall response rate was 26% (CR: 1 pt, PR: 12 pts; PR not confirmed yet in 3 pts), and 44% (22 pts) had stable disease over 1.5−7.5 months (median: 3). Only 30% (15 pts) had disease progression at the first evaluation at week 6. The hematological grade 3/4 toxicities according to NCI CTAE 3.0 were thrombocytopenia 10% (5 pts), neutropenia 8% (4 pts), lymphopenia and leucocytopenia each 2% (1 pt). Cumulative non-hematological toxicities grade 3/4 were nausea and fatigue each 6% (3 pts), hypertension, vomiting and hemorrhage, each 4% (2 pts), thrombosis/embolism, infection, constipation, anorexia, elevation of alkaline phosphatase, bilirubin, GGT, ALT and AST each 2% (1 pt). Conclusion: In metastatic melanoma the combination of Tem/Bev is a safe regimen with a promising efficacy and few grade 3/4 toxicities. Updated results of all 62 pts will be presented.